Skip to main content
. 2015 May 26;112(23):7327–7332. doi: 10.1073/pnas.1502076112

Table S4.

Expression profile of glycogenes not predicted to be targets of the miR-200 family in MDA-MB-231 cells treated with miR-200a, miR-200b, or scramble mimics

miR-200a treatment miR-200b treatment
Glycogene Fold change P value Glycogene Fold change P value
A4GNT −1.41 7.2E-03 A4GNT −1.81 1.1E-03
AGA −1.37 2.5E-03 AGA −1.17 0.24
B3GNT3 13.51 5.8E-06 B3GNT3 67.80 1.4E-05
B3GNT8 −1.14 0.42 B3GNT8 1.01 0.95
B4GALT1 −1.17 0.20 B4GALT1 −1.15 0.16
B4GALT2 1.01 0.97 B4GALT2 −1.02 0.92
B4GALT3 1.21 0.43 B4GALT3 1.32 0.19
B4GALT5 1.11 0.62 B4GALT5 1.61 2.1E-02
C1GALT1C1 −1.01 0.94 C1GALT1C1 1.02 0.80
EDEM1 −1.07 0.59 EDEM1 −1.05 0.65
EDEM2 −1.06 0.60 EDEM2 1.04 0.66
EDEM3 1.02 0.79 EDEM3 −1.10 0.23
FUCA1 −1.09 0.31 FUCA1 −1.12 0.19
FUCA2 −1.09 0.24 FUCA2 −1.03 0.61
FUT8 1.20 0.19 FUT8 −1.07 0.45
FUT11 1.03 0.79 FUT11 1.28 0.12
GALNT1 1.15 0.29 GALNT1 −1.12 0.30
GALNT6 2.14 3.7E-04 GALNT6 1.79 9.9E-05
GALNT7 −1.07 0.60 GALNT7 −1.09 0.39
GALNT8 −1.69 0.21 GALNT8 −2.07 0.18
GALNT9 −2.19 0.12 GALNT9 −1.90 0.17
GALNT13 −1.16 2.4E-02 GALNT13 1.03 0.63
GALNTL1 −1.61 1.3E-02 GALNTL1 −2.02 3.3E-03
GALNTL5 1.41 0.69 GALNTL5 1.08 0.94
GALNTL6 −2.06 0.12 GALNTL6 −3.08 4.8E-02
GANAB −1.01 0.92 GANAB −1.02 0.80
GCNT1 −1.61 8.1E-05 GCNT1 −1.63 4.0E-03
GCNT3 −1.18 0.35 GCNT3 1.49 0.23
GLB1 −1.06 0.73 GLB1 −1.17 0.26
GNPTAB −1.15 0.19 GNPTAB −1.03 0.84
GNPTG −1.15 0.26 GNPTG −1.13 0.22
HEXA −1.11 0.36 HEXA −1.14 9.1E-02
HEXB −1.13 0.24 HEXB −1.17 0.11
MAN1A1 1.09 0.54 MAN1A1 −1.14 0.45
MAN1A2 1.02 0.88 MAN1A2 −1.15 0.25
MAN1B1 −1.06 0.56 MAN1B1 −1.08 0.41
MAN1C1 −1.07 0.76 MAN1C1 −1.39 3.9E-02
MAN2A1 −1.06 0.23 MAN2A1 1.13 0.23
MAN2A2 1.24 0.41 MAN2A2 1.43 0.12
MAN2B1 1.04 0.89 MAN2B1 1.01 0.97
MANBA −1.21 5.5E-04 MANBA −1.22 1.5E-02
MGAT1 1.18 0.36 MGAT1 1.37 1.9E-02
MGAT4B 1.13 0.39 MGAT4B 1.13 0.17
MGAT5 1.27 0.32 MGAT5 1.31 0.25
MGAT5B −1.29 0.15 MGAT5B −2.24 3.7E-03
MOGS 1.10 0.63 MOGS 1.32 9.2E-02
NAGPA −1.33 0.32 NAGPA −1.40 0.20
NEU1 −1.08 0.63 NEU1 1.25 0.10
NEU2 1.43 0.24 NEU2 1.62 3.2E-02
NEU3 −1.05 0.63 NEU3 1.24 7.4E-02
NEU4 −1.35 0.51 NEU4 −1.63 0.36
OGT −1.09 0.50 OGT −1.02 0.88
POFUT2 −1.14 0.18 POFUT2 −1.25 1.4E-02
POMGNT1 1.06 0.71 POMGNT1 −1.05 0.59
POMT1 −1.18 0.33 POMT1 −1.07 0.61
POMT2 1.07 0.66 POMT2 1.02 0.85
PRKCSH 1.02 0.86 PRKCSH 1.07 0.39
ST3GAL1 1.19 5.6E-02 ST3GAL1 1.21 2.7E-02
ST6GAL1 −1.60 8.5E-03 ST6GAL1 −2.08 3.8E-04
ST6GALNAC1 4.57 4.4E-02 ST6GALNAC1 9.10 6.1E-03
ST8SIA3 −1.11 0.91 ST8SIA3 −1.06 0.95
ST8SIA6 −1.72 1.7E-02 ST8SIA6 −3.13 1.8E-03
UGGT1 −1.03 0.87 UGGT1 −1.15 0.30
UGGT2 −1.09 0.44 UGGT2 −1.18 9.3E-02

MDA-MB-231 cells were treated with miR-200a, miR-200b, or scramble mimics (50 nM) for 7 d. qRT-PCR was performed using RT2 Profiler PCR Array Human Glycosylation (Qiagen). Fold change (miR-treated/scramble-treated) was calculated by taking the average relative expression of miR-treated samples (n = 4 independent experiments, normalized to GAPDH) over the average relative expression of the scramble-treated cells (n = 4 independent experiments, normalized to GAPDH). Where the fold change was less than 1, the negative inverse is shown. P values for treated vs. scramble were calculated using Student's t-test. Statistically significant (P ≤ 0.05) down-regulation is in bold type, and statistically significant up-regulation is underlined.